Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1IB4Q)

• Drug Name: Zolmitriptan Drug Info
• Synonyms: AscoTop; Flezol; Zolmitriptane; Zolmitriptanum; Zomig; Zomigon; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zomig Nasal Spray; Zomig ZMT; AscoTop (TN); BW-311C90; KS-5072; Zomig (TN); Zomig-ZMT; Zomigon (TN); Zomigoro (TN); Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
• Therapeutic Class: Antimigraine Agents
• Cross-matching ID:
  PubChem CID: 60857
  ChEBI ID: CHEMBL1185
  CAS Number: CAS 139264-17-8
  TTD Drug ID: D0NG7O
  VARIDT Drug ID: DR01278
  INTEDE Drug ID: DR1733
  ACDINA Drug ID: D00743

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Pyrimidine metabolism	1.98	1.05e-2	40/56 (71.43%)	DPYD;TYMS;DCTPP1;...
Hematopoietic cell lineage	-1.72	2.96e-2	90/99 (90.91%)	IL1R2;CD1B;HLA-DRB1;...
Fat digestion and absorption	-1.74	2.55e-2	35/43 (81.4%)	DGAT1;FABP1;AGPAT1;...
Antigen processing and presentation	-1.75	2.75e-2	60/78 (76.92%)	HLA-A;HLA-DPB1;HSPA1A;...
Fatty acid elongation	-1.82	9.56e-3	19/27 (70.37%)	HACD1;ELOVL4;ACAA2;...
Graft-versus-host disease	-1.85	9.56e-3	32/42 (76.19%)	HLA-DRB1;HLA-A;HLA-DPB1;...
Arrhythmogenic right ventricular cardiomyopathy	-1.85	9.56e-3	70/77 (90.91%)	TCF7L2;DSC2;CACNA2D2;...
PPAR signaling pathway	-1.90	7.17e-3	66/74 (89.19%)	PPARD;HMGCS2;FABP1;...
Biosynthesis of unsaturated fatty acids	-1.92	6.37e-3	21/27 (77.78%)	HSD17B4;HACD1;ELOVL4;...
Allograft rejection	-1.93	4.78e-3	32/38 (84.21%)	HLA-DRB1;HLA-A;HLA-DPB1;...
Autoimmune thyroid disease	-2.14	0.00e+0	46/53 (86.79%)	PRF1;HLA-DRA;TSHB;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼